Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Leerink Partners Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $60
Leerink Partners analyst Faisal Khurshid initiates coverage on $Kymera Therapeutics(KYMR.US)$ with a buy rating, and sets the target price at $60.According to TipRanks data, the analyst has a
Express News | Kymera Therapeutics Inc : Leerink Partners Assumes Coverage With Outperform Rating; Target Price $60
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics Shares Rise After Wolfe Research Upgrade